Tags

Type your tag names separated by a space and hit enter

Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Cancer. 2008 Apr 01; 112(7):1513-21.C

Abstract

BACKGROUND

Evaluation of therapeutic outcomes and risk factors was undertaken for patients with primary solid tumors (PST) developing acute leukemia or myelodysplasia (MDS) as a second malignancy.

METHODS

In all, 131 consecutive patients presenting to a single institution with leukemia or MDS after treatment for PST with surgery or chemotherapy/radiotherapy were examined. Management of the secondary acute leukemia and MDS consisted either of intensive therapy including allogeneic blood and marrow transplants or supportive measures.

RESULTS

The time from diagnosis of PST to development of acute leukemia or MDS, the cytogenetic profile of patients, and their survival were similar irrespective of PST therapy with surgery alone or strategies involving chemotherapy and/or radiation. The median survival of all 131 patients was 10.5 months with a 5-year survival of 15.6%. Induction therapy and/or transplantation resulted in a median survival of 13.6 months and a 5-year survival of 26.6% compared with 6.5 months and 2% with supportive measures. Subset analysis of transplant recipients revealed a median survival of 17.6 months and a 37.9% 5-year survival. Despite a significantly lower recurrence rate the survival of transplant recipients was not improved secondary to a higher treatment-related mortality (TRM) rate.

CONCLUSIONS

Patients developing acute leukemia or MDS after PST demonstrated similar cytogenetic profiles and clinical outcomes independent of the type of treatment. Survival was significantly better for patients able to undergo intensive therapy compared with supportive measures. The low recurrence rate for allograft recipients was consistent with a potent antileukemic effect that may translate into a survival benefit if TRM could be reduced.

Authors+Show Affiliations

Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18286528

Citation

Abdelhameed, Arwa, et al. "Outcome of Patients Who Develop Acute Leukemia or Myelodysplasia as a Second Malignancy After Solid Tumors Treated Surgically or With Strategies That Include Chemotherapy And/or Radiation." Cancer, vol. 112, no. 7, 2008, pp. 1513-21.
Abdelhameed A, Pond GR, Mitsakakis N, et al. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer. 2008;112(7):1513-21.
Abdelhameed, A., Pond, G. R., Mitsakakis, N., Brandwein, J., Chun, K., Gupta, V., Kamel-Reid, S., Lipton, J. H., Minden, M. D., Schimmer, A., Schuh, A., Yee, K., & Messner, H. A. (2008). Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer, 112(7), 1513-21. https://doi.org/10.1002/cncr.23325
Abdelhameed A, et al. Outcome of Patients Who Develop Acute Leukemia or Myelodysplasia as a Second Malignancy After Solid Tumors Treated Surgically or With Strategies That Include Chemotherapy And/or Radiation. Cancer. 2008 Apr 1;112(7):1513-21. PubMed PMID: 18286528.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. AU - Abdelhameed,Arwa, AU - Pond,Gregory R, AU - Mitsakakis,Nicholas, AU - Brandwein,Joseph, AU - Chun,Kathy, AU - Gupta,Vikas, AU - Kamel-Reid,Suzanne, AU - Lipton,Jeffrey H, AU - Minden,Mark D, AU - Schimmer,Aaron, AU - Schuh,Andre, AU - Yee,Karen, AU - Messner,Hans A, PY - 2008/2/21/pubmed PY - 2008/5/7/medline PY - 2008/2/21/entrez SP - 1513 EP - 21 JF - Cancer JO - Cancer VL - 112 IS - 7 N2 - BACKGROUND: Evaluation of therapeutic outcomes and risk factors was undertaken for patients with primary solid tumors (PST) developing acute leukemia or myelodysplasia (MDS) as a second malignancy. METHODS: In all, 131 consecutive patients presenting to a single institution with leukemia or MDS after treatment for PST with surgery or chemotherapy/radiotherapy were examined. Management of the secondary acute leukemia and MDS consisted either of intensive therapy including allogeneic blood and marrow transplants or supportive measures. RESULTS: The time from diagnosis of PST to development of acute leukemia or MDS, the cytogenetic profile of patients, and their survival were similar irrespective of PST therapy with surgery alone or strategies involving chemotherapy and/or radiation. The median survival of all 131 patients was 10.5 months with a 5-year survival of 15.6%. Induction therapy and/or transplantation resulted in a median survival of 13.6 months and a 5-year survival of 26.6% compared with 6.5 months and 2% with supportive measures. Subset analysis of transplant recipients revealed a median survival of 17.6 months and a 37.9% 5-year survival. Despite a significantly lower recurrence rate the survival of transplant recipients was not improved secondary to a higher treatment-related mortality (TRM) rate. CONCLUSIONS: Patients developing acute leukemia or MDS after PST demonstrated similar cytogenetic profiles and clinical outcomes independent of the type of treatment. Survival was significantly better for patients able to undergo intensive therapy compared with supportive measures. The low recurrence rate for allograft recipients was consistent with a potent antileukemic effect that may translate into a survival benefit if TRM could be reduced. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/18286528/Outcome_of_patients_who_develop_acute_leukemia_or_myelodysplasia_as_a_second_malignancy_after_solid_tumors_treated_surgically_or_with_strategies_that_include_chemotherapy_and/or_radiation_ L2 - https://doi.org/10.1002/cncr.23325 DB - PRIME DP - Unbound Medicine ER -